0 Site Credits
You currently have 0 Site Credits in your account. Purchase Site Credits
Section: Non-CECH Category: Promotional

A Scientifically Designed Topical Treatment for Toenail Onychomycosis JUBLIA® (efinaconazole) Topical Solution, 10%

Warren Joseph, DPM, FIDSA

Onychomycosis has been a consistent topic at podiatric and dermatology conferences since the first truly effective FDA approved oral antifungal, terbinafine, was approved in the late 1990s. Therapeutically, the major change in the intervening 20 years has been the approvals of the prescription topical therapies; ciclopirox lacquer, effinaconazole solution and tavaborole solution. Dr. Joseph will present topics that traditionally have not been discussed in detail in the majority of onychomycosis presentations. These include the emergence of antifungal resistance, primarily to the previous “Gold Standard” antifungal terbinafine, some unique aspects of the molecular diagnosis of fungal infections, and, finally, examine the evidence for the use of over-the-counter topical antifungal products that are available at local pharmacies and being dispense in podiatrist’s offices.

Goals and Objectives
  1. Recognize that increasing rates of resistance to antifungal drugs, such as terbinafine, may begin to limit their clinical usefulness.
  2. Understand the microbiology of antifungal resistance and how it may be minimized with appropriate therapy
  3. Appreciate the strict standards set by the FDA to approve new antifungal agents for the treatment of onychomycosis
  4. Identify the clinical evidence in the literature to support the use of the marketed OTC agents
  • Author
  • Warren Joseph, DPM, FIDSA

    Adjunct Clinical Professor
    Arizona College of Podiatric Medicine at Midwestern University
    Glendale, AZ Editor - Journal of the APMA

  • System Requirements
  • To view Lectures online, the following specs are required:

    • Broadband Internet
    • Browsers must have javascript enabled. Most browsers have this feature enabled by default.
    • Any PDF reader. Download Adobe PDF (Free) to print certificates.
    Supported Browsers:
    • Chrome
    • Firefox
    • Microsoft Edge
    • Safari
    Supported Mobile OS:
    • Apple iOS 13+
    • Android 10+
  • Disclosure Information
  • It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.


    Warren Joseph has disclosed that he is a consultant/speaker's bureau for Ortho Dermatologics; an advisor to Paratek.